Search

  • Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Journal Of Epileptology

 

Case report | 11-March-2014

Successful treatment with adjunctive lacosamide in a patient with long term “drug resistant” focal epilepsy

, seizure-freedom was never achieved even though he was treated with twelve to fourteen different AEDs during this time. Intensive presurgical evaluations did not allow identification of a surgically remediable focus. Adjunctive treatment with lacosamide 400 mg/day was not successful. However, the patient became seizure-free immediately after an increase of the lacosamide dose up to 500 mg/day. The patient is now seizure-free for more than two years based on a combination of 500 mg lacosamide and 350 mg

Walter Fröscher, Alois Rauber

Journal of Epileptology, Volume 22 , ISSUE 1, 51–55

review-article | 04-April-2020

Treatment with lacosamide or levetiracetam in patients with renal replacement therapy. What is really known?

BACKGROUND Lacosamide (LCM) was t approved in 2008 for the management of partial-onset seizures. Plasma protein binding for LCM is low (approximately < 15%) in healthy subjects. Approximately 40% of the dose is eliminated in the urine as unchanged active drug. Overall, 94% of the dose is eliminated in the urine within 168 hours, mainly as inactive metabolites. It has demonstrated no clinically relevant pharmacokinetic drug-drug interactions (Cawello, 2015). Levetiracetam (LEV) obtained initial

Maya Cuhls, Julian Bösel, Johannes Rösche

Journal of Epileptology, Volume 28 , 33–36

No Record Found..
Page Actions